Determination of Dermatology Life Quality Index Criteria in Libyan Pemphigus Patients

Hussein Osman

Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

Tarik Enaairi

Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

Ghait Alsdae

Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

Gamal Duweb *

Department of Dermatology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

*Author to whom correspondence should be addressed.


Abstract

Introduction: The term "pemphigus" describes a group of uncommon autoimmune dermatoses of the mucocutaneous membranes caused by acantholysis, or the breakdown of cell-to-cell adhesion, which can result in the production of potentially fatal bullae and erosion. Based on their unique clinical characteristics and pathogenesis, several subtypes of pemphigus illness have been discovered. These subtypes include paraneoplastic pemphigus (PNP), IgA pemphigus, pemphigus vulgaris (PV), and pemphigus foliaceus (PF).

Aim of the Study: To measure the Dermatology Life Quality Index (DLQI) in Libyan pemphigus patients and assess the impact of the disease on their lives.

Materials and Methods: In this descriptive study, 25 patients with pemphigus attending Bullous Clinic, dermatology department, Jumhoria Hospital, Benghazi, Libya, over one year from January to December 2021, were enrolled. All patients were registered in the clinic, and the diagnosis of pemphigus was confirmed by histopathology. For every patient, the DLQI score was measured by filling out the questionnaire.

Results:  Of the 25 patients with pemphigus included in this study, 5 patients (20%) were male and 20 patients (80%) were female. The age ranged from 30 to 72 years, and the mean age was 43.64 years. The duration of the disease ranged from 1 to 408 months (mean: 83.12 months). Pemphigus folaiceous was encountered in 13 patients (52%). Concerning disease severity, 44% of cases presented with a severe illness. In 15 patients (60%), mucous membranes were not involved. Eight patients (32%) were treated with steroids (Prednisolone) and cytotoxic (Azathioprine) drugs. The mean DLQI scores for pemphigus vulgaris were 12.67 and for pemphigus folaiceous were 10.31. Dermatology Qualify Life Index (DLQI) scores showed a large effect on life quality in 56% of the study cases and a moderate effect in 32% of them.

Conclusion: Pemphigus has a substantial impact on Libyan patients' DLQI scores; individuals receiving systemic combination treatment were shown to have lower scores.

Keywords: Pemphigus, pemphigus vulgaris, demographic features, dermatology life quality index (DLQI), Libya


How to Cite

Osman , H., Enaairi , T., Alsdae , G., & Duweb , G. (2024). Determination of Dermatology Life Quality Index Criteria in Libyan Pemphigus Patients. Asian Journal of Research in Dermatological Science, 7(1), 1–9. Retrieved from https://journalajrdes.com/index.php/AJRDES/article/view/98

Downloads

Download data is not yet available.

References

Simon DG, Krutchkoff D, Kaslow AR, et al. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch. Dermatol. 1980;116:1035–1037.

Bastuji-Garin S, Souissi R, Blum L, et al. Comparative Epidemiology of Pemphigus in Tunisia and France: Unusual Incidence of Pemphigus Foliaceus in Young Tunisian Women. J. Investig. Dermatol. 1995;104:302–305.

Wilson C, Wojnarowska F, Mehra N, et al. Pemphigus in Oxford, UK, and New Delhi, India: A Comparative Study of Disease Characteristics and HLA Antigens. Dermatology. 1994;189((Suppl. 1)):108–110.

Kridin K, Zelber-Sagi S. Bergman R. Pemphigus Vulgaris and Pemphigus Foliaceus: Differences in Epidemiology and Mortality. Acta Derm. Venereol. 2017; 97:1095–1099.

Ahmed AR, Wagner R, Khatri K, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA. 1991;88:5056–5060.

Ahmed AR, Yunis EJ, Khatri K, et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. USA. 1990;87:7658–7662.

Krain LS. Increased frequency of HL-A10 in pemphigus vulgaris. Arch. Dermatol. 1973;108:803–805.

Mobini N, Yunis EJ, Alper CA, et al. Identical MHC markers in non-Jewish Iranian and Ash-kenazi Jewish patients with pemphigus vulgaris: Possible common central Asian ancestral origin. Hum. Immunol. 1997;57:62–67.

Krain RL, Kushner CJ, Tarazi M, et al. Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus. Frontiers in immunology. 2019;6(10):2571.

James J, Sadasivan Jayakrishnan AE. Demography and health-related quality of life of patients with pemphigus vulgaris and bullous pemphigoid treated at a tertiary care hospital: A cross-sectional study. Journal of Skin and Sexually Transmitted Diseases Volume. 2022;4(2):233.

Padniewski JJ, Shaver RL, Schultz B, et al. Patient quality of life improvement in bullous disease: A review of primary literature and considerations for the clinician. Clinical, Cosmetic and Investigational Dermatology. 2022;10:27-42.

Tee CT, Lee CS, Gunabalasingam P. Characteristics and quality of life in pemphigus patients. The Medical Journal of Malaysia. 2022;77(3):324-30.

Tallab T, Joharji H, Bahamdan K, et. al. The incidence of pemphigus in the southern region of Saudi Arabia. Int. J. Dermatol. 2001;40:570–572.

Laskaris G, Stoufi E. Oral pemphigus vulgaris in a 6-year-old girl. Oral Surg. Oral Med. Oral Pathol. 1990;69:609–613.

WHOQOL Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.Soc Sci Med. 1995; 41:1403–9.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210– 16.

Basra MK, Fenech R, Gatt RM et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997– 1030.

Both H, Essink-Bot ML, Busschbach J et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2726–39.

Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004; 9:169– 80.

Bashyam AM, Feldman SR, Dermatology Life Quality Index: does improving the instrument make it better?, British Journal of Dermatology. 2019;182(5):1082-1083. DOI:10.1111/bjd.18598,

Sebaratnam DF, Okawa J, Payne A, et al. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. Qual Life Res. 2015;24:2257–60.

Paradise A, Sampogna F, Di Pietro C, et al. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol. 2009;60:261–9.

Paradisi A, Cianchini G, Lupi F, et al. Quality of life in patients with pemphigus receiving adjuvant therapy. Clin Exp Dermatol. 2012;37:626–30.

Yang B, Chen G, Yang Q, et al. Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. Health Qual Life Outcomes. 2017;15:31.

Mayrshofer F, Hertl M, Sinkgraven R, et al. Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group. J Dtsch Dermatol Ges. 2005;3:431–5.

Terrab Z, Benchikhi H, Maaroufi A, et al. Quality of life and pemphigus. Ann Dermatol Venereol. 2005;132:321–8.

Sung JY, Roh MR, Kim SC. Quality of life assessment in korean patients with Pemphigus. Ann Dermatol. 2015;27:492–8.

Chee SN, Murrell DF. Pemphigus and quality of life. Dermatol Clin. (2011) 29:521–5.

Pena S, Payne A, Stanley J, et al. Quality of life in autoimmune blistering diseases (AIBD). J Invest Dermatol. 2017;137:S67.

Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, et al. Quality of life and psychological status of patients with pemphigus vulgaris using dermatology life quality index and general health questionnaires. J Dermatol. 2012;39:141–4.

Sebaratnam DF, McMillan JR, Werth VP, et al. Quality of life in patients with bullous dermatoses. Clin Dermatol. 2012;30:103–7.

Payne AS. Quantifying disease extent in pemphigus. Br J Dermatol. 2016;175:18–9. DOI: 10.1111/bjd.14562.

Mayrshofer F, Hertl M, Sinkgraven R. Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group. J Dtsch Dermatol Ges. 2005;3:431–5.

Wysoczyńska K, Żebrowska A, Waszczykowska E. Quality of life in patients with pemphigus. Dermatology Review/Przeglad Dermatologiczny. 2013; 100(3):139–145.

Rencz F, Gulácsi L, Tamási B, et al. Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. Br J Dermatol. 2015;173 (4): 1076–1080. DOI:10.1111/bjd.13848.